Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 1/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.54 |
| ▸ | MME | P08473 | 3/20 | 0.51 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | CPA1 | P15085 | 2/20 | 0.51 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GGT1 | P19440 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668355 | 1.00 | BCHE (0.58) | BCHEFAAHMMEACECPA1 | |
| SCHEMBL249801 | 0.95 | BCHE (0.54) | BCHEFAAHMMEACECPA1 | |
| SCHEMBL249802 | 0.95 | BCHE (0.54) | BCHEFAAHMMEACECPA1 | |
| SCHEMBL3143813 | 0.95 | BCHE (0.54) | BCHEFAAHMMEACECPA1 | |
| Ethylenediamine SCHEMBL9008938 | 0.94 | BCHE (0.54) | BCHEFAAHMMEACECPA1 | |
| Ethylenediamine SCHEMBL9008941 | 0.94 | BCHE (0.54) | BCHEFAAHMMEACECPA1 | |
| SCHEMBL6702717 | 0.94 | FAAH (0.55) | BCHEFAAHMMEACECPA1 | |
| SCHEMBL6702715 | 0.94 | FAAH (0.55) | BCHEFAAHMMEACECPA1 | |
| SCHEMBL21585496 | 0.94 | FAAH (0.55) | BCHEFAAHMMEACECPA1 | |
| SCHEMBL3953856 | 0.94 | FAAH (0.55) | BCHEFAAHMMEACECPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023219933-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACID THERAPEUTICS | ENTRADA THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | claimed |
| EP-3291826-A1 | ANTI-BACTERIAL AGENTS AND THEIR USE IN THERAPY | Norwegian University of Science and Technology (NTNU) (NO) | 2018-03-14 | — | — | EP | claimed |
| WO-2016177899-A9 | ANTI-BACTERIAL AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2016-12-29 | — | — | WO | claimed |
| WO-2016177899-A1 | ANTI-BACTERIAL AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2016-11-10 | — | — | WO | claimed |
| EP-3065759-A1 | IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY | Norwegian University of Science and Technology (NTNU) (NO) | 2016-09-14 | — | — | EP | claimed |
| CN-105143245-A | Anti-scaling material | YISSUM RES DEV CO | 2015-12-09 | — | — | CN | claimed |
| WO-2015067712-A1 | IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPY | NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU) (NO) | 2015-05-14 | — | — | WO | claimed |
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | PALATIN TECHNOLOGIES, INC. (US) | 2023-02-09 | — | — | US | disclosed |
| EP-4100040-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| EP-4100042-A1 | REVERSE AMIDE-LINKED MELANOCORTIN RECEPTOR-SPECIFIC CYCLIC PEPTIDES | Palatin Technologies, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| US-20220204450-A1 | Orally Active Melanocortin Receptor-4 Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2021158463-A1 | DIAMINE-LINKED RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2021158464-A1 | REVERSE AMIDE-LINKED MELANOCORTIN RECEPTOR-SPECIFIC CYCLIC PEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| WO-2007098420-A2 | PEPTIDES THAT BLOCK THE BINDING OF IGG TO FCRN | SYNTONIX PHARMACEUTICALS, INC. (US) | 2007-08-30 | — | — | WO | disclosed |
| EP-1263471-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066147-A2 | ANTIMICROBIAL COMPOUNDS AND FORMULATIONS | ALPHARMA AS (NO) | 2001-09-13 | — | — | WO | disclosed |
| EP-0773956-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | Aventis Pharma S.A. (FR) | 1997-05-21 | — | — | EP | disclosed |
| US-5582814-A | COMPLEX OF PARAMAGNETIC METAL AND 1-/PARA-BUTYLBENZYL/DIETHYLENETRIAMINEPENTAACETIC ACID | METASYN, INC. (US) | 1996-12-10 | — | — | US | disclosed |
| WO-1996004298-A1 | PURIFIED FORM OF STREPTOGRAMINES, PREPARATION OF SAME AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | RHONE-POULENC RORER S.A. (FR) | 1996-02-15 | — | — | WO | disclosed |
| WO-1995028179-A1 | CONTRAST AGENTS FOR DIAGNOSTIC IMAGING | METASYN, INC. (US) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040236-A1 | Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications | MC1R, MC3R, MC5R | BCHE 2523/4885FAAH 1293/4885MME 139/4885 |
| US-20220204450-A1 | Orally Active Melanocortin Receptor-4 Compounds | MC4R, MC1R, MC3R | BCHE 4239/4885FAAH 2873/4885MME 1216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.